Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.

te Beek ET, Hay JL, Bullman JN, Burgess C, Nahon KJ, Klaassen ES, Gray FA, van Gerven JM.

Br J Clin Pharmacol. 2013 May;75(5):1328-39. doi: 10.1111/bcp.12004.

PMID:
23067311
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Placebo- and amitriptyline-controlled evaluation of central nervous system effects of the NK1 receptor antagonist aprepitant and intravenous alcohol infusion at pseudo-steady state.

te Beek ET, Tatosian D, Majumdar A, Selverian D, Klaassen ES, Petty KJ, Gargano C, van Dyck K, McCrea J, Murphy G, van Gerven JM.

J Clin Pharmacol. 2013 Aug;53(8):846-56. doi: 10.1002/jcph.120. Epub 2013 Jun 18.

PMID:
23775877
[PubMed - indexed for MEDLINE]
3.

Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state.

te Beek ET, Zoethout RW, Bani MS, Andorn A, Iavarone L, Klaassen ES, Fina P, van Gerven JM.

J Psychopharmacol. 2012 Feb;26(2):303-14. doi: 10.1177/0269881111431750. Epub 2012 Jan 4.

PMID:
22219221
[PubMed - indexed for MEDLINE]
4.

Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.

Liem-Moolenaar M, Rad M, Zamuner S, Cohen AF, Lemme F, Franson KL, van Gerven JM, Pich EM.

Br J Clin Pharmacol. 2011 Jun;71(6):907-16. doi: 10.1111/j.1365-2125.2011.03902.x.

PMID:
21223356
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects.

Liem-Moolenaar M, Zoethout RW, de Boer P, Schmidt M, de Kam ML, Cohen AF, Franson KL, van Gerven JM.

J Psychopharmacol. 2010 Nov;24(11):1681-7. doi: 10.1177/0269881109105573. Epub 2009 Jul 31.

PMID:
19648218
[PubMed - indexed for MEDLINE]
6.

Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.

Liem-Moolenaar M, Gray FA, de Visser SJ, Franson KL, Schoemaker RC, Schmitt JA, Cohen AF, van Gerven JM.

J Psychopharmacol. 2010 Jan;24(1):73-82. doi: 10.1177/0269881108094524. Epub 2008 Aug 28.

PMID:
18755817
[PubMed - indexed for MEDLINE]
7.

Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans.

Hoch M, Hay JL, Hoever P, de Kam ML, te Beek ET, van Gerven JM, Dingemanse J.

Eur Neuropsychopharmacol. 2013 Feb;23(2):107-17. doi: 10.1016/j.euroneuro.2012.04.012. Epub 2012 May 30.

PMID:
22658401
[PubMed - indexed for MEDLINE]
8.

The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.

Liem-Moolenaar M, Zoethout RW, de Boer P, Schmidt M, de Kam ML, Cohen AF, Franson KL, van Gerven JM.

J Psychopharmacol. 2010 Nov;24(11):1671-9. doi: 10.1177/0269881109106942. Epub 2010 Feb 8.

PMID:
20142308
[PubMed - indexed for MEDLINE]
9.

Central nervous system effects of haloperidol on THC in healthy male volunteers.

Liem-Moolenaar M, te Beek ET, de Kam ML, Franson KL, Kahn RS, Hijman R, Touw D, van Gerven JM.

J Psychopharmacol. 2010 Nov;24(11):1697-708. doi: 10.1177/0269881109358200. Epub 2010 Feb 8.

PMID:
20142302
[PubMed - indexed for MEDLINE]
10.

Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET.

Ridler K, Gunn RN, Searle GE, Barletta J, Passchier J, Dixson L, Hallett WA, Ashworth S, Gray FA, Burgess C, Poggesi I, Bullman JN, Ratti E, Laruelle MA, Rabiner EA.

J Psychopharmacol. 2014 Mar;28(3):244-53. doi: 10.1177/0269881113517953. Epub 2014 Jan 15.

PMID:
24429221
[PubMed - indexed for MEDLINE]
11.

Evaluation of the cognitive, psychomotor and pharmacokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers.

Barbanoj MJ, García-Gea C, Antonijoan R, Izquierdo I, Donado E, Pérez I, Solans A, Jané F.

Hum Psychopharmacol. 2006 Jan;21(1):13-26.

PMID:
16389668
[PubMed - indexed for MEDLINE]
12.

Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers.

Dumont GJ, Schoemaker RC, Touw DJ, Sweep FC, Buitelaar JK, van Gerven JM, Verkes RJ.

J Psychopharmacol. 2010 Feb;24(2):155-64. doi: 10.1177/0269881108099214. Epub 2009 Jan 22.

PMID:
19164498
[PubMed - indexed for MEDLINE]
13.

Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists.

Hanessian S, Babonneau V, Boyer N, Mannoury la Cour C, Millan MJ, De Nanteuil G.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):510-4. doi: 10.1016/j.bmcl.2013.12.033. Epub 2013 Dec 15.

PMID:
24374277
[PubMed - indexed for MEDLINE]
14.

Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.

Liem-Moolenaar M, de Boer P, Timmers M, Schoemaker RC, van Hasselt JG, Schmidt S, van Gerven JM.

Br J Clin Pharmacol. 2011 Jun;71(6):886-98. doi: 10.1111/j.1365-2125.2011.03936.x.

PMID:
21306419
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers.

Wesnes KA, Garratt C, Wickens M, Gudgeon A, Oliver S.

Br J Clin Pharmacol. 2000 Feb;49(2):110-7.

PMID:
10671904
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.

te Beek ET, Moerland M, de Boer P, van Nueten L, de Kam ML, Burggraaf J, Cohen AF, van Gerven JM.

J Psychopharmacol. 2012 Aug;26(8):1119-27. doi: 10.1177/0269881111415733. Epub 2011 Sep 2.

PMID:
21890591
[PubMed - indexed for MEDLINE]
18.

The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation.

van Steveninck AL, van Berckel BN, Schoemaker RC, Breimer DD, van Gerven JM, Cohen AF.

J Psychopharmacol. 1999;13(1):10-7.

PMID:
10221355
[PubMed - indexed for MEDLINE]
19.

Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain.

Sanger GJ.

Br J Pharmacol. 2004 Apr;141(8):1303-12. Epub 2004 Mar 15. Review.

PMID:
15023866
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

Foster RH, Goa KL.

CNS Drugs. 1997 Aug;8(2):163-88. doi: 10.2165/00023210-199708020-00010.

PMID:
23338224
[PubMed]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk